Agenda

2025 Diagnostics Accelerator (DxA) Day

The full-day symposium will be broken into a morning and afternoon session that features presentations by DxA-funded investigators and two panels convening industry experts.

‍Breakfast and lunch will be served. Coffee and refreshments will be available throughout the day.

All Sessions

Morning Session: Today - Implementing p-tau217 and Other Proven Diagnostics

8:00 –

8:30 am

BREAKFAST

8:30 –

8:45 am

Opening Remarks

Howard Fillit, MD, ADDF
Mark Roithmayr, ADDF

8:45 –

9:05 am

DxA Portfolio Overview: Shaping the Future of Alzheimer's Through Biomarker Innovation

Laura Nisenbaum, PhD, ADDF

9:05 –

9:10 am

Overview of Morning Session

Aishu Sukumar, MBA, MPH, Gates Ventures

9:10 –

9:40 am

Keynote Presentation: Recent Developments in Biomarkers for Alzheimer’s Disease

Oskar Hansson, MD, PhD, Lund University, Eli Lilly

9:40 –

9:50 am

Keynote Q&A Session

Oskar Hansson, MD, PhD, Lund University, Eli Lilly

9:50 –

10:55 am

Panel 1: Focusing on the Current Diagnostic Landscape for Alzheimer’s, From Development to Implementation

Moderator:
Nick Ashton, PhD, Banner Health

Panelists:
Joel Braunstein, MD, MBA, C2N
Danielle Graham, PhD, Biogen
Oskar Hansson, MD, PhD, Lund University/ Eli Lilly
Cecilia Lee, MD, MS, University of Washington
Zivjena Vucetic, MD, PhD, Beckman Coulter

‍

10:55 –

11:15 am

Coffee Break

11:15 –

11:35 am

Refining the Assessment of Amyloid Pathology: Update on Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio

Manu Vandijck, Fujirebio

11:35 –

11:55 am

Differences In p-tau217 Blood Tests and an Effort to Standardize

Nick Ashton, PhD, Banner Health

11:55 –

12:55 pm

LUNCH

Afternoon Session: Tomorrow & Beyond - Exploring Innovative Opportunities for Precision Medicine

12:55 –

1:00 pm

Overview of Afternoon Session

Eli Shobin, PhD, ADDF

1:00 –

1:20 pm

Remote and Unsupervised Detection and Monitoring of Memory Decline in Alzheimer’s Disease

David Berron, PhD, neotiv GmbH

1:20 –

1:40 pm

Molecular Heterogeneity in Alzheimer's Disease

Betty Tijms, PhD, Amsterdam UMC

1:40 –

2:00 pm

Accelerating Biomarker Discovery and Diagnostics for Alzheimer’s Disease With the NULISA™ Proteomics Platform

Xiao-Jun Ma, PhD, Alamar Biosciences
Yuling Luo, PhD, Alamar Biosciences

‍

2:00 –

2:10 pm

Coffee Break

2:10 –

2:30 pm

SpeechDx: A Gold-Standard Speech-and-Language Dataset for Prognostic AD Biomarker Development

Melissa Lee, PhD, ADDF, SpeechDx

2:30 –

3:20 pm

Panel 2: The Future of Alzheimer’s Biomarkers: Blood, Digital, Speech and Beyond

Moderator:
Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas

Panelists:
Howard Fillit, MD, ADDF
Rhoda Au, PhD, Boston University
Mark Mintun, MD, Eli Lilly
Charlotte Teunissen, PhD, Amsterdam UMC
Betty Tijms, PhD, Amsterdam UMC
Pallavi Sachdev, PhD, Eisai
Henrik Zetterberg, MD, PhD, University of Gothenburg

3:20 –

3:30 pm

Wrap Up

Mark Roithmayr, ADDF

Morning Session

8:00 –

8:30 am

BREAKFAST

8:30 –

8:45 am

Opening Remarks

Howard Fillit, MD, ADDF
Mark Roithmayr, ADDF

8:45 –

9:05 am

DxA Portfolio Overview: Shaping the Future of Alzheimer's Through Biomarker Innovation

Laura Nisenbaum, PhD, ADDF

9:05 –

9:10 am

Overview of Morning Session

Aishu Sukumar, MBA, MPH, Gates Ventures

9:10 –

9:40 am

Keynote Presentation: Recent Developments in Biomarkers for Alzheimer’s Disease

Oskar Hansson, MD, PhD, Lund University, Eli Lilly

9:40 –

9:50 am

Keynote Q&A Session

Oskar Hansson, MD, PhD, Lund University, Eli Lilly

9:50 –

10:55 am

Panel 1: Focusing on the Current Diagnostic Landscape for Alzheimer’s, From Development to Implementation

Moderator:
Nick Ashton, PhD, Banner Health

‍

10:55 –

11:15 am

Coffee Break

11:15 –

11:35 am

Refining the Assessment of Amyloid Pathology: Update on Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio

Manu Vandijck, Fujirebio

11:35 –

11:55 am

Differences In p-tau217 Blood Tests and an Effort to Standardize

Nick Ashton, PhD, Banner Health

11:55 –

12:55 pm

LUNCH

Afternoon Session

12:55 –

1:00 pm

Overview of Afternoon Session

Eli Shobin, PhD, ADDF

1:00 –

1:20 pm

Remote and Unsupervised Detection and Monitoring of Memory Decline in Alzheimer’s Disease

David Berron, PhD, neotiv GmbH

1:20 –

1:40 pm

Molecular Heterogeneity in Alzheimer's Disease

Betty Tijms, PhD, Amsterdam UMC

1:40 –

2:00 pm

Accelerating Biomarker Discovery and Diagnostics for Alzheimer’s Disease With the NULISA™ Proteomics Platform

Xiao-Jun Ma, PhD, Alamar Biosciences
Yuling Luo, PhD, Alamar Biosciences

‍

2:00 –

2:10 pm

Coffee Break

2:10 –

2:30 pm

SpeechDx: A Gold-Standard Speech-and-Language Dataset for Prognostic AD Biomarker Development

Melissa Lee, PhD, ADDF, SpeechDx

2:30 –

3:20 pm

Panel 2: The Future of Alzheimer’s Biomarkers: Blood, Digital, Speech and Beyond

Moderator:
Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas

3:20 –

3:30 pm

Wrap Up

Mark Roithmayr, ADDF